Eli Lilly and Company (LLY) — Quantitative Forecast & Factor Scores

LLY currently carries a valuation grade of Buy. At a trailing P/E of 39.9, the stock trades at a 82% premium to the Healthcare sector median of 22.0x. Our discounted cash flow model suggests an intrinsic range of $870–$1,594, implying a +34% margin of safety at the current price of $918.05.

With a beta of 0.43, LLY exhibits a low-volatility risk profile relative to the broad market. Net margins of 31.7% are significantly above the Healthcare average of 18%, reflecting strong pricing power. Return on equity of 101.2% indicates highly efficient capital allocation. Leverage is moderate with debt-to-equity at 165%.

With a 25% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a +17.9% earnings surprise. Analyst estimate revisions are trending accelerating.

Insiders have been net sellers to the tune of $4,194,226,195 recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 0.9% of float, suggesting limited bearish conviction.

The options market shows a put/call ratio of 1.30, reflecting a notably bearish skew in derivative positioning. Implied and realized volatility are roughly aligned at 38.7% and 35.2% respectively.

As a Healthcare constituent, LLY's risk profile should be evaluated alongside sector peers when constructing diversified portfolios.